Summary
This New Strategic Report from Espicom Provides A Comprehensive Review of Current and Future Treatments for Major Blood Cancer Therapy Areas: Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Acute Myeloid Leukaemia, Multiple Myeloma and Non-Hodgkin's Lymphoma.
Over 275 Pages of Product Analysis, Market Statistics and Forecasts Unique Market Share and 5-Year Sales Forecasts for Leading Products & Pipeline Prospects A Comprehensive Examination of Major Blood Cancer Therapy Areas Critical Competitive Evaluation and Scoring of Current and Future Products.
Providing...
- Detailed Analysis and 5-Year Forecasts for Current Leading Products by Value
- A Detailed Review and Assessment of up and Coming Products
- Unique Product Assessment and Scoring
- An Evaluation of The Current Understanding of Blood Cancers
Major Areas Covered
- Chronic Lymphocytic Leukaemia
- Chronic Myeloid Leukaemia
- Acute Myeloid Leukaemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
The Report Covers Major Blood Cancer Areas
- Chronic Lymphocytic Leukaemia
- Chronic Myeloid Leukaemia
- Acute Myeloid Leukaemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
The Market
- Risk Factors, How The Disease Affects Patients, Diagnosis and Stages of The Disease
- The Market in 2007 and 2012
- Growth Drivers and Dampeners
Patient Statistics
- Prevalence
- Diagnosis Rates
- Unmet Clinical Need
Current Treatment Options
- Interventions by Type
- Unique Five Point Competitive Assessment and Scoring of Current Therapies and Companies Involved
- 5-Year Sales Forecasts for Key Products
R&d: Drugs in Late Stage Development
- Focus on New Classes of Drugs and The Companies Involved
- Unique Competitive Assessment and Scoring of New Therapies and Companies Involved
- 5-Year Sales Forecasts for Key Products from Year of Launch
Extensive Tables and Charts
|
